N

Nykode Therapeutics ASA
OSE:NYKD

Watchlist Manager
Nykode Therapeutics ASA
OSE:NYKD
Watchlist
Price: 2.812 NOK 4.38% Market Closed
Market Cap: 918.2m NOK
Have any thoughts about
Nykode Therapeutics ASA?
Write Note

Nykode Therapeutics ASA
Other Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Nykode Therapeutics ASA
Other Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
N
Nykode Therapeutics ASA
OSE:NYKD
Other Operating Expenses
-$32.5m
CAGR 3-Years
-11%
CAGR 5-Years
-67%
CAGR 10-Years
N/A
Hofseth Biocare ASA
OSE:HBC
Other Operating Expenses
-kr87.4m
CAGR 3-Years
-13%
CAGR 5-Years
-23%
CAGR 10-Years
-9%
B
Bergenbio ASA
OSE:BGBIO
Other Operating Expenses
-kr107.3m
CAGR 3-Years
21%
CAGR 5-Years
8%
CAGR 10-Years
N/A
L
Lytix Biopharma AS
OSE:LYTIX
Other Operating Expenses
-kr12.3m
CAGR 3-Years
-61%
CAGR 5-Years
-30%
CAGR 10-Years
N/A
Arcticzymes Technologies ASA
OSE:AZT
Other Operating Expenses
-kr34.7m
CAGR 3-Years
-36%
CAGR 5-Years
-16%
CAGR 10-Years
-9%
T
Thor Medical ASA
OSE:TRMED
Other Operating Expenses
-kr11.7m
CAGR 3-Years
66%
CAGR 5-Years
47%
CAGR 10-Years
9%
No Stocks Found

Nykode Therapeutics ASA
Glance View

Market Cap
918.2m NOK
Industry
Biotechnology

Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo and currently employs 135 full-time employees. The company went IPO on 2020-01-27. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The firm develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The firm also has two universal COVID-19 vaccine candidates in development.

NYKD Intrinsic Value
0.181 NOK
Overvaluation 94%
Intrinsic Value
Price
N

See Also

What is Nykode Therapeutics ASA's Other Operating Expenses?
Other Operating Expenses
-32.5m USD

Based on the financial report for Jun 30, 2024, Nykode Therapeutics ASA's Other Operating Expenses amounts to -32.5m USD.

What is Nykode Therapeutics ASA's Other Operating Expenses growth rate?
Other Operating Expenses CAGR 5Y
-67%

Over the last year, the Other Operating Expenses growth was 28%. The average annual Other Operating Expenses growth rates for Nykode Therapeutics ASA have been -11% over the past three years , -67% over the past five years .

Back to Top